Gainers
- Atlis Motor Vehicles Inc (NASDAQ:AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday.
- Silo Pharma, Inc. (NASDAQ:SILO) rose 105% to $10.46 in pre-market trading following uplisting to the Nasdaq.
- Biogen Inc. (NASDAQ:BIIB) shares rose 39.7% to $276.32 in pre-market trading. Biogen and Eisai Co. announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.
- Prothena Corporation plc (NASDAQ:PRTA) rose 37.4% to $42.50 in pre-market trading in sympathy with Biogen.
- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) rose 29.8% to $6.10 in pre-market trading after gaining around 6% on Tuesday.
- Flora Growth Corp. (NASDAQ:FLGC) rose 17.9% to $0.8621 in pre-market trading after dropping 8% on Tuesday.
- MorphoSys AG (NASDAQ:MOR) rose 17.7% to $5.24 in pre-market trading.
- Longeveron Inc. (NASDAQ:LGVN) rose 16.9% to $4.71 in pre-market trading. Longeveron, last month, received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS)..
- AIM ImmunoTech Inc. (NYSE:AIM) rose 16.4% to $0.6750 in pre-market trading after declining around 7% on Tuesday.
- ASAP, Inc. (NASDAQ:WTRH) rose 12.1% to $0.1793 in pre-market trading after declining around 9% on Tuesday.
- Windtree Therapeutics, Inc. (NASDAQ:WINT) rose 12% to $0.35 in pre-market trading.
- BioVie Inc. (NASDAQ:BIVI) rose 11.8% to $2.64 in pre-market trading. BioVie recently announced topline results from an investigator-sponsored Phase 2 clinical trial of NE3107 for the treatment of Alzheimer's Disease, saying "vast majority of patients saw significant improvements in the Global Rating of Change."
- Locafy Limited (NASDAQ:LCFY) rose 10.5% to $0.42 in pre-market trading after declining around 6% on Tuesday.
- Cassava Sciences, Inc. (NASDAQ:SAVA) rose 10.2% to $50.90 in pre-market trading. Shares of companies with potential Alzheimer's treatments trading higher premarket in sympathy with Biogen.
- Quanterix Corporation (NASDAQ:QTRX) rose 9.2% to $8.80 in pre-market trading.
- Lilly and Company (NYSE:LLY) rose 7.7% to $335.00 in pre-market trading. Shares of companies with potential Alzheimer's treatments trading higher premarket in sympathy with Biogen.
Don’t forget to check out our premarket coverage here .
Losers
- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) fell 34.8% to $3.99 in pre-market trading as the company reported pricing of public offering of common shares and warrants.
- iBio, Inc. (NYSE:IBIO) shares fell 31.6% to $0.2162 in pre-market trading after the company reported FY22 preliminary sales results and announced a 1-for-25 reverse stock split.
- Nano Labs Ltd (NASDAQ:NA) fell 23% to $2.45 in pre-market trading after the company priced its 2.08 million ADS public offering at $2.40 per ADS.
- Gamida Cell Ltd. (NASDAQ:GMDA) fell 21.4% to $1.54 in pre-market trading after the company priced 12.9 nm share public offering of common stock at $1.55 per share.
- Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) fell 14% to $0.5161 in pre-market trading after surging 19% on Tuesday.
- EZGO Technologies Ltd. (NASDAQ:EZGO) fell 13% to $0.40 in pre-market trading.
- Avenue Therapeutics, Inc. (NASDAQ:ATXI) fell 12.3% to $6.37 in pre-market trading. The stock has been volatile after the company last week announced a 1-for-15 reverse split and received meeting minutes from the FDA regarding a meeting conducted on August 9, 2022, for IV Tramadol.
- MFA Financial, Inc. (NYSE:MFA) shares fell 10.8% to $7.90 in pre-market trading after the company filed for mixed-securities shelf offering.
- Presto Automation, Inc (NASDAQ:PRST) fell 10.4% to $2.41 in pre-market trading. The company recently completed its previously announced business combination with Ventoux CCM Acquisition.
- MoneyLion Inc. (NYSE:ML) shares fell 8.3% to $1.00 in pre-market trading.
- Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares fell 7.9% to $1.05 in pre-market trading. Aquestive Therapeutics recently announced positive topline results from the EPIPHAST 2 trial for its AQST-109 epinephrine sublingual film.
- 9 Meters Biopharma, Inc. (NASDAQ:NMTR) fell 7.6% to $0.1980 in pre-market trading. 9 Meters Biopharma recently announced final results from the Phase 2 VIBRANT study and a successful End-of-Phase 2 meeting with the FDA for vurolenatide in short bowel syndrome.
- Deutsche Bank Aktiengesellschaft (NYSE:DB) fell 6.8% to $7.20 in pre-market trading. CFTC ordered 11 financial institutions to pay over $710 million for recordkeeping, supervision failures for widespread use of unapproved communication methods.
- Sandstorm Gold Ltd. (NYSE:SAND) fell 6.6% to $5.20 in pre-market trading after the company announced an $80 million bought deal financing.
- Credit Suisse Group AG (NYSE:CS) fell 5% to $3.78 in pre-market trading. CFTC ordered 11 financial institutions to pay over $710 million for recordkeeping, supervision failures for widespread use of unapproved communication methods.
